Key result
DOACs cut stroke and systemic embolism ~21% vs. VKAs in AF patients with cancer.
Why the study?
Several observational studies have investigated DOACs versus VKAs in patients with both AF and cancer, warranting a comprehensive overview of the real-world evidence.
Does direct oral anticoagulant therapy reduce stroke or systemic embolism and major bleeding compared to vitamin K antagonists in patients with atrial fibrillation and concurrent cancer?
Meta-Analysis (n=84,491)
Yes
Does direct oral anticoagulant therapy reduce stroke or systemic embolism and major bleeding compared to vitamin K antagonists in patients with atrial fibrillation and concurrent cancer?
In real-world observational cohorts of patients with atrial fibrillation and concurrent cancer, DOACs are associated with significantly lower risks of stroke/systemic embolism and major, intracranial, and gastrointestinal bleeding compared with VKAs.
Answers are grounded in this paper and cite their sources.
Supports DOAC preference over VKAs in AF with cancer; extends observational meta-analysis but leaves definitive adoption open pending RCTs.
Hig hlights • DOACs are associated with a reduced risk of stroke or systemic embolism and major bleeding events compared to VKAs in AF patients with cancer. • DOACs are associated with lower rates of intracranial and gastrointestinal bleeding in cancer patients with AF. • Real-world evidence favors DOACs as a favorable treatment option for AF patients with cancer. Several observational cohort studies have been conducted to investigate the effectiveness and safety of direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) in patients who have both atrial fibrillation (AF) and cancer. Herein, we conducted a meta -analysis to present a comprehensive overview of the real-world evidence on DOACs in patients with AF and cancer. A comprehensive search strategy was performed in PubMed and Embase until February 2024 for studies that enrolled AF patients with cancer who received DOACs or VKAs. The adjusted risk ratios (RRs) and 95% confidence intervals (CIs) of each outcome were extracted and pooled by a random-effects model. Seven observational cohort studies were eligible for data extraction. The random-effects model analysis indicated that compared with VKA use, the use of DOACs was significantly associated with reduced risks of stroke or systemic embolism (RR=0.79, 95 % CI 0.64–––0.97), major bleeding (RR=0.84, 95 % CI 0.71–––0.99), intracranial bleeding (RR=0.61, 95 % CI 0.54–––0.69), and gastrointestinal bleeding (RR=0.87, 95 % CI 0.80–––0.95) in AF patients with concurrent cancer. Compared with VKAs, the use of DOACs was associated with decreased risks of thrombotic and bleeding events in AF patients with cancer. Data from real-world scenarios support the use of DOACs as a favorable treatment option for this specific patient population.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) conducted a meta-analysis in Atrial fibrillation with concurrent cancer (n=84,491). Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, or edoxaban) vs. Vitamin K antagonists (primarily warfarin) was evaluated on Stroke or systemic embolism (SSE) (RR 0.79, 95% CI 0.64-0.97). Direct oral anticoagulants reduced the risk of stroke or systemic embolism and major bleeding compared with vitamin K antagonists in AF patients with cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: